መነሻHDP1 • FRA
add
Arrowhead Pharmaceuticals Inc
የቀዳሚ መዝጊያ
€25.85
የቀን ክልል
€25.67 - €25.67
የዓመት ክልል
€19.52 - €36.69
የገበያው አጠቃላይ ዋጋ
3.58 ቢ USD
የዋጋ/ገቢ ምጥጥን
-
የትርፍ ክፍያ
-
ዋና ልውውጥ
NASDAQ
ዜና ላይ
ፋይናንስ
የገቢ መግለጫ
ገቢ
የተጣራ ገቢ
(USD) | ማርች 2024info | ከዓመት ዓመት ለውጥ |
---|---|---|
ገቢ | — | — |
የሥራ ወጪ | 126.19 ሚ | 28.63% |
የተጣራ ገቢ | -125.30 ሚ | -357.42% |
የተጣራ የትርፍ ክልል | — | — |
ገቢ በሼር | -1.02 | -326.67% |
EBITDA | -121.67 ሚ | -339.34% |
ውጤታማ የግብር ተመን | — | — |
ቀሪ ሒሳብ ሉሆች
አጠቃላይ ንብረቶች
አጠቃላይ ተጠያቂነቶች
(USD) | ማርች 2024info | ከዓመት ዓመት ለውጥ |
---|---|---|
ጥሬ ገንዘብና የአጭር ጊዜ መዋዕለ ንዋይ | 520.91 ሚ | 8.30% |
አጠቃላይ ንብረቶች | 955.15 ሚ | 7.16% |
አጠቃላይ ተጠያቂነቶች | 459.74 ሚ | 7.87% |
አጠቃላይ እሴት | 495.40 ሚ | — |
የሼሮቹ ብዛት | 124.20 ሚ | — |
የገበያ ዋጋ እና የተገለጸ ዋጋ | 6.63 | — |
የእሴቶች ተመላሽ | -39.90% | — |
የካፒታል ተመላሽ | -43.18% | — |
የገንዘብ ፍሰት
የተጣራ ዝርዝር ገንዘብ በጥሬ ገንዘብ
(USD) | ማርች 2024info | ከዓመት ዓመት ለውጥ |
---|---|---|
የተጣራ ገቢ | -125.30 ሚ | -357.42% |
ከክወናዎች የተገኘ ጥሬ ገንዘብ | -92.38 ሚ | -191.68% |
ገንዘብ ከኢንቨስትመንት | -268.94 ሚ | -645.70% |
ገንዘብ ከፋይናንስ | 430.78 ሚ | 82,741.73% |
የተጣራ ዝርዝር ገንዘብ በጥሬ ገንዘብ | 69.49 ሚ | 203.27% |
ነፃ የገንዘብ ፍሰት | -91.82 ሚ | -262.49% |
ስለ
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. Wikipedia
ዋና ሥራ አስፈጻሚ
የተመሰረተው
1 ጃን 2004
ዋና መሥሪያ ቤት
ድህረገፅ
ሠራተኞች
525